Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05940272 · ClinicalTrials.gov registry record · NA
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
A NA study of Lymphoma and Lymphoma, B-Cell, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 48
- Enrollment target
- 2
- Study locations
NCT05940272: Recruiting NA study of Lymphoma and Lymphoma, B-Cell, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05940272 is a NA study of Lymphoma and Lymphoma, B-Cell that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 48 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05940272, a NA study of Lymphoma and Lymphoma, B-Cell, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.
Primary Outcome
Feasbility is defined as ≥70% of screened eligible hematologists and participants enrolling in the study and ≥80% of hematologists learning the approach
Conditions Studied
Interventions
- BEHAVIORAL Hematolo-GIST Training
- BEHAVIORAL Participants Appointment
Study Locations (2)
New York
- Memorial Sloan Kettering Cancer Center (All protocol activities) - New York
- NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-07-03 |
| Est. Completion | 2028-07-03 |
| Phase | NA |
What NCT05940272 shows while recruiting
NCT05940272 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower).
The record links to 6 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Hematolo-GIST Training is the first listed.
NCT05940272 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05940272 about?
NCT05940272 is a clinical study titled "Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers". The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.
What is the current status of trial NCT05940272?
This trial is currently recruiting. It is a NA study. The enrollment target is 48 participants. The study started on 2023-07-03. Estimated completion is 2028-07-03.
What conditions does trial NCT05940272 study?
This clinical trial studies the following conditions: Lymphoma, Lymphoma, B-Cell, Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma, Large-cell Lymphoma.
What interventions are being tested in trial NCT05940272?
The interventions under investigation include: Hematolo-GIST Training (BEHAVIORAL), Participants Appointment (BEHAVIORAL).
Who is sponsoring clinical trial NCT05940272?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05940272 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05940272's enrollment target sits among peer trials
48 157th of 299 higher than 141 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
RECRUITING · NA
-
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
RECRUITING · NA
-
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation
RECRUITING · NA
-
UPLYFT For Lymphoma Survivors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI